A Metrologically Traceable Candidate Reference Measurement Procedure (cRMP) for Dehydroepiandrosterone Sulfate in Human Serum Based on Isotope Dilution‐Liquid Chromatography–Tandem Mass Spectrometry (ID‐LC–MS/MS)
Journal of Mass Spectrometry · 2026
DOI: 10.1002/jms.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mass Spectrometry, 2026. Verfasst von Liping Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Reference System Center, Maccura Biotechnology Co., Ltd, Chengdu, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Dehydroepiandrosterone Sulfate, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Non-communicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Dehydroepiandrosterone sulfate (DHEAS), a crucial steroid hormone for adrenal function and pubertal development, is highly associated with related diseases. This study aims to develop and validate an isotope dilution liquid chromatography tandem mass spectrometry (ID‐LC–MS/MS)‐based candidate reference measurement procedure (cRMP) for quantifying serum DHEAS. Serum samples were prepared by protein precipitation with acetonitrile and separated on a reversed phase column. Assay validation was conducted under the guidance of standard documents, including C62‐A, EP6‐A, EP10‐A3, and C50‐P endorsed by the Clinical and Laboratory Standards Institute (CLSI). The cRMP was established and proven to be highly specific without significant matrix effect and able to accurately quantify DHEAS in human serum. The intra‐assay and inter‐assay imprecision ranged from < 0.1 to 1.0% and from 1.0 to 1.1%, respectively. Trueness was assessed by recovery rate from 99.6 to 101.2%. The limit of detection (LoD) was 0.270 nmol/L, and the lower limit of the measuring interval (LLMI) was 12.1 nmol/L. A linear correlation ranged from 7.60 to 41 858 nmol/L was observed with a correlation coefficient > 0.999. R 2 value of linear regression analysis between this method and clinical immunoassays was ≥ 0.990. The relative expanded uncertainty was 1.5%–2.5% over the concentration range of 12.1–33 043 nmol/L. This study developed an ID‐LC–MS/MS‐based cRMP, which provided high specificity, trueness, and precision for serum DHEAS quantification, contributing to the DHEAS measurement standardization and traceability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reference System Center, Maccura Biotechnology Co., Ltd, Chengdu, China.
- Key Laboratory of Chemical Metrology and Applications on Nutrition, Health, State Administration for Market Regulation, Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, Ch…
ORCID-Profile: Bingling Gao
Förderung
- Non-communicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Yang, L., Gao, B., Yang, T., Tang, L., Kan, Y., Sun, K., & Xiao, P. (2026). A Metrologically Traceable Candidate Reference Measurement Procedure (cRMP) for Dehydroepiandrosterone Sulfate in Human Serum Based on Isotope Dilution‐Liquid Chromatography–Tandem Mass Spectrometry (ID‐LC–MS/MS). Journal of Mass Spectrometry. https://doi.org/10.1002/jms.70088
Vancouver
Yang L, Gao B, Yang T, Tang L, Kan Y, Sun K, et al. A Metrologically Traceable Candidate Reference Measurement Procedure (cRMP) for Dehydroepiandrosterone Sulfate in Human Serum Based on Isotope Dilution‐Liquid Chromatography–Tandem Mass Spectrometry (ID‐LC–MS/MS). Journal of Mass Spectrometry. 2026. doi:10.1002/jms.70088
BibTeX
@article{Yang2026,
author = {Yang, Liping and Gao, Bingling and Yang, Tao and Tang, Liping and Kan, Ying and Sun, Keqi and Xiao, Peng},
title = {A Metrologically Traceable Candidate Reference Measurement Procedure (cRMP) for Dehydroepiandrosterone Sulfate in Human Serum Based on Isotope Dilution‐Liquid Chromatography–Tandem Mass Spectrometry (ID‐LC–MS/MS)},
journal = {Journal of Mass Spectrometry},
year = {2026},
doi = {10.1002/jms.70088}
}
EUVIMED